Alzheon returns, with a $47M NIH grant and one last shot at a pivotal PhIII Alzheimer’s success
Alzheon has spent four years searching for investors, public or private, willing to back a large study for their once-failed Alzheimer’s drug. On Thursday, they finally found a benefactor.
The NIH’s Institute for Aging awarded Alzheon $47 million over the next five years for a pivotal Phase III trial on their lead drug, ALZ-801. It’s not the IPO that CEO and founder Martin Tolar wanted — and twice filed for — but the company says it will be enough to start study they have wanted to get off the ground for four years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
